Global Analysis of Multitrial Data Investigating Quality of Life and Symptoms as Prognostic Factors for Survival in Different Tumor Sites

被引：164

作者：

Quinten, Chantal ^{[1
]}

Martinelli, Francesca ^{[1
]}

Coens, Corneel ^{[1
]}

Sprangers, Mirjam A. G. ^{[2
]}

Ringash, Jolie ^{[3
]}

Gotay, Carolyn ^{[4
]}

Bjordal, Kristin ^{[5
]}

Greimel, Eva ^{[6
]}

Reeve, Bryce B. ^{[7
]}

Maringwa, John ^{[1
]}

Ediebah, Divine E. ^{[1
]}

Zikos, Efstathios ^{[1
]}

King, Madeleine T. ^{[8
]}

Osoba, David ^{[9
]}

Taphoorn, Martin J. ^{[10
]}

Flechtner, Henning ^{[11
]}

Schmucker-Von Koch, Joseph ^{[12
]}

Weis, Joachim ^{[13
]}

Bottomley, Andrew ^{[1
]}

机构：

[1] EORTC Headquarters, Qual Life Dept, B-1200 Brussels, Belgium

[2] Univ Amsterdam, Acad Med Ctr, Dept Med Psychol, NL-1105 AZ Amsterdam, Netherlands

[3] Univ Toronto, Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON, Canada

[4] Univ British Columbia, Sch Populat & Publ Hlth, British Columbia Canc Res Ctr, Vancouver, BC V5Z 1M9, Canada

[5] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[6] Med Univ Graz, Graz, Austria

[7] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA

[8] Univ Sydney, Psychooncol Cooperat Res Grp, Sydney, NSW 2006, Australia

[9] Qual Life Consulting, W Vancouver, BC, Canada

[10] Med Ctr Haaglanden, VU Med Ctr, Amsterdam, Netherlands

[11] Univ Magdeburg, D-39106 Magdeburg, Germany

[12] Univ Regensburg, D-93053 Regensburg, Germany

[13] Univ Freiburg, Dept Psychooncol, Tumorbiol Ctr, D-79106 Freiburg, Germany

来源：

CANCER | 2014年 / 120卷 / 02期

关键词：

cancer; quality of life; patient-reported outcomes; multi trial; prognostic factors; PATIENT-REPORTED OUTCOMES; CELL LUNG-CANCER; RANDOMIZED CONTROLLED-TRIAL; ADVANCED COLORECTAL-CANCER; CLINICAL-TRIALS; BREAST-CANCER; EUROPEAN-ORGANIZATION; PREDICTING SURVIVAL; ESOPHAGEAL CANCER; HEALTH;

D O I：

10.1002/cncr.28382

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUNDThe objective of this study was to examine the prognostic value of baseline health-related quality of life (HRQOL) for survival with regard to different cancer sites using 1 standardized and validated patient self-assessment tool. METHODSIn total, 11 different cancer sites pooled from 30 European Organization for Research and Treatment of Cancer (EORTC) randomized controlled trials were selected for this study. For each cancer site, univariate and multivariate Cox proportional hazards modeling was used to assess the prognostic value (P<.05) of 15 HRQOL parameters using the EORTC Core Quality of Life Questionnaire (QLQ-C30). Models were adjusted for age, sex, and World Health Organization performance status and were stratified by distant metastasis. RESULTSIn total, 7417 patients completed the EORTC QLQ-C30 before randomization. In brain cancer, cognitive functioning was predictive for survival; in breast cancer, physical functioning, emotional functioning, global health status, and nausea and vomiting were predictive for survival; in colorectal cancer, physical functioning, nausea and vomiting, pain, and appetite loss were predictive for survival; in esophageal cancer, physical functioning and social functioning were predictive for survival; in head and neck cancer, emotional functioning, nausea and vomiting, and dyspnea were predictive for survival; in lung cancer, physical functioning and pain were predictive for survival; in melanoma, physical functioning was predictive for survival; in ovarian cancer, nausea and vomiting were predictive for survival; in pancreatic cancer, global health status was predictive for survival; in prostate cancer, role functioning and appetite loss were predictive for survival; and, in testis cancer, role functioning was predictive for survival. CONCLUSIONSThe current results demonstrated that, for each cancer site, at least 1 HRQOL domain provided prognostic information that was additive over and above clinical and sociodemographic variables. Cancer 2014;120:302-311. (c) 2013 American Cancer Society. Quality-of-life parameters provide prognostic survival information over and above what is provided by clinical and sociodemographic variables. Although clinicians tend to view quality of life as a soft endpoint, there is a wealth of information that it can bring to clinicians; and, as such, quality of life is gaining momentum.

引用

页码：302 / 311

页数：10

共 49 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2]

[Anonymous], 2006, GUID IND PAT REP OUT

[3] Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes [J].

Basch, Ethan ;

Jia, Xiaoyu ;

Heller, Glenn ;

Barz, Allison ;

Sit, Laura ;

Fruscione, Michael ;

Appawu, Mark ;

Iasonos, Alexia ;

Atkinson, Thomas ;

Goldfarb, Shari ;

Culkin, Ann ;

Kris, Mark G. ;

Schrag, Deborah .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23) :1624-1632

[4] Factors predicting survival in patients with advanced oesophageal cancer:: a prospective multicentre evaluation [J].

Bergquist, H. ;

Johnsson, A. ;

Hammerlid, E. ;

Wenger, U. ;

Lundell, L. ;

Ruth, M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (05) :385-395

[5] A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients [J].

Bjordal, K ;

de Graeff, A ;

Fayers, PM ;

Hammerlid, E ;

van Pottelsberghe, C ;

Curran, D ;

Ahlner-Elmqvist, M ;

Maher, EJ ;

Meyza, JW ;

Brédart, A ;

Söderholm, AL ;

Arraras, JJ ;

Feine, JS ;

Abendstein, H ;

Morton, RP ;

Pignon, T ;

Huguenin, P ;

Bottomly, A ;

Kaasa, S .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) :1796-1807

[6] The prognostic value of quality of life scores during treatment for oesophageal cancer [J].

Blazeby, JM ;

Brookes, ST ;

Alderson, D .

GUT, 2001, 49 (02) :227-230

[7] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group [J].

Bottomley, Andrew ;

Coens, Corneel ;

Suciu, Stefan ;

Santinami, Mario ;

Kruit, Willem ;

Testori, Alessandro ;

Marsden, Jeremy ;

Punt, Cornelis ;

Sales, Francois ;

Gore, Martin ;

MacKie, Rona ;

Kusic, Zvonko ;

Dummer, Reinhard ;

Patel, Poulam ;

Schadendorf, Dirk ;

Spatz, Alain ;

Keilholz, Ulrich ;

Eggermont, Alexander .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :2916-2923

[8] Quality of life assessment as a predictor of survival in non-small cell lung cancer [J].

Braun, Donald P. ;

Gupta, Digant ;

Staren, Edgar D. .

BMC CANCER, 2011, 11

[9] The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval [J].

Burke, L. B. ;

Kennedy, D. L. ;

Miskala, P. H. ;

Papadopoulos, E. J. ;

Trentacosti, A. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) :281-283

[10] Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data [J].

Chou, I ;

Norman, AR ;

Cunningham, D ;

Waters, JS ;

Oates, J ;

Ross, PJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2395-2403

← 1 2 3 4 5 →